Workers at AbbVie’s manufacturing facility in Carrigtwohill, Ireland—one of six plants the Illinois drugmaker runs in the ...

For investors in gene therapy biotech bluebird bio, a wait-and-see approach toward a proposed acquisition has paid off. | For ...

Despite holding the lead with its complement inhibitor Syfovre, Apellis Pharmaceuticals is discovering that the geographic ...

Famar, a portfolio company of the private equity firm of MidEuropa, is set to acquire a sterile manufacturing facility in ...

With massive social media hype around its intricate world-building and steamy love scenes, perhaps no literary genre has made ...

With a late-stage trial win for its Norditropin heir in hand, Novo Nordisk is making good on plans to boost its profile in ...

Roche’s Herceptin and Perjeta duo is already part of a well-established standard of care in early-stage HER2-positive breast ...

Thanks to hefty sales increases from kidney disease drug Kerendia and prostate cancer treatment Nubeqa, Bayer’s pharma ...

Mayne Pharma is in trouble with the FDA. The agency accused Mayne of giving a misleading impression of the risks of its oral ...

Bluebird bio shareholders have dragged their feet in tendering shares as part of the company’s sale process, prompting buyers ...

About a month after disclosing a $50 billion investment in its U.S. | Roche has earmarked more than $700 million to construct ...

On a quest to expand the eligible patient pool for its fast-growing liver disease drug Rezdiffra, Madrigal Pharmaceuticals ...